



Press Release

March 19, 2007

Immunomic Therapeutics, Inc.
9290 Gaither Road
Gaithersburg, MD 20877

Ph: 240-731-5232
Fax: 240-597-4061
info@immunomictherapeutics.com
www.immunomix.com

FOR IMMEDIATE RELEASE: March 19, 2007 (Gaithersburg, MD)

Immunomic Therapeutics Selected to Present at Three Investor Conferences

Gaithersburg, MD, March 19 2007 /-- Immunomic Therapeutics, Inc. (ITI, www.immunomix.com) announced today that the Company has been selected to present at three important investor conferences: the Philadelphia Angel Venture Fair, to be held on April 24, 2007, at the BioBusiness Forum as part of the Bio 2007 Annual Meeting (May 6-9, 2007) and at the World's Best Technology Showcase, May 15 – 16, 2007.

The **Angel Venture Fair** (www.angelventurefair.com) selects approximately 20 companies to present from over 200 regional applicants and offers the selected companies an opportunity to promote their business to some of the regions most active angel groups. According to their website, over 70% of presenting companies in 2006 received funding.

The **BioBusiness Forum** is perhaps the industry's most premier event since it is held as part of the massive Bio 2007 (www.bio2007.org) Annual Meeting. ITI will be presenting along side some of the best recognized names in the industry and will be meeting with investors and potential collaborators in a dynamic environment.

ITI is also presenting at the WBT Showcase (www.wbtshowcase.com), a meeting that features the best technology transfer companies using technologies licensed from university and government laboratories. The WBT event was also a competition where ITI was selected from among many applicants.

Dr. Bill Hearl, President & CEO of Immunomic Therapeutics said, "I am very pleased and excited to have been selected by the selection committees for each of these important events. The fact that a ITI was chosen as a featured company by diverse groups of reviewers is an indication of the potential for our LAMP Vaccines. We are looking forward to very successful presentations of the Company."

About Immunomic Therapeutics

Immunomic Therapeutics was founded in 2005 as a joint effort between Capital Genomix, Inc. and Johns Hopkins University to commercialize the LAMP Technology for cancer, infectious disease and other targets. The core technology is based on the research efforts of Dr. J. Thomas August that began in the mid-1990's studying intracellular molecular trafficking in dendritic cells. LAMP was found to locate within the cell in the same compartment as the Major Histocompatibility Complex – type II (MHC-II). It was shown that an antigenic protein linked to LAMP would also migrate to the MHC-II compartment. This observation had important ramifications to the development of DNA-based vaccines and Dr. August and JHU were awarded a patent in 1997 for the application of LAMP to genetic vaccines. More recent research has led to the filing of additional patents covering improvements and enhancements for DNA – based vaccines.

Immunomic Therapeutics, Inc. ("ITI") is a privately held biotechnology company headquartered in Gaithersburg, Maryland that is commercializing a portfolio of clinical applications based on "LAMP" vaccine technology. ITI offers access to LAMP – based vectors and novel vaccine design through license and collaborative research agreements. More information about ITI and LAMP technology can be obtained from www.immunomix.com or www.immunomictherapeutics.com.

This press release may contain forward looking statements regarding, among other matters, the Company's future prospects. Forward looking statements address matters that are subject to a number of risks and uncertainties that can cause actual results to differ materially. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of ITI's technologies, constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Future results of the Company will depend on a variety of factors, including the timing of significant orders, the ability of the Company to timely manufacture and deliver ordered products, the ability of the Company to bring new systems to market, the timing of new product releases by the Company's competitors and other competitive factors.

CONTACT:

Immunomic Therapeutics, Inc.
Bill Hearl, Ph.D., President & CEO
240-731-5232
info@immunomictherapeutics.com